Related Experiment Video

Updated: Jun 22, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

Elevation of intracellular cyclic AMP inhibits NF-kappaB-mediated thymosin beta4 expression in melanoma cells

Aeyung Kim1, Minsik Son, Keun Il Kim

  • 1Department of Biological Science, Sookmyung Women's University, Seoul, Republic of Korea.

Experimental Cell Research
|June 9, 2009
PubMed

Insights

Elevated cyclic AMP (cAMP) reduces thymosin beta4 (Tbeta4) expression and suppresses melanoma cell metastasis by inhibiting NF-kappaB activation. This finding is crucial for developing new anti-cancer therapies targeting tumor progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Thymosin beta4 (Tbeta4) is a key protein linked to tumor growth, survival, and metastasis.
  • Downregulating Tbeta4 is a critical target for anti-cancer drug development.

Purpose of the Study:

  • To investigate how elevated cyclic AMP (cAMP) affects Tbeta4 expression and melanoma cell metastatic potential.
  • To elucidate the molecular mechanisms behind cAMP-mediated Tbeta4 suppression.

Main Methods:

  • Murine B16 melanoma cells (B16F10) were treated with cAMP-inducing agents (alpha-MSH, IBMX).
  • Tbeta4 expression, NF-kappaB activation, EMT-associated genes, and cell invasiveness were analyzed.
  • In vivo experiments assessed the metastatic potential of treated melanoma cells.

Main Results:

  • Alpha-MSH and IBMX significantly suppressed Tbeta4 expression in B16F10 cells.
  • cAMP induction inhibited NF-kappaB activation and reduced the expression of EMT-associated genes.
  • In vitro invasiveness and in vivo metastatic potential of melanoma cells were decreased.

Conclusions:

  • Elevated intracellular cAMP effectively suppresses Tbeta4 expression and reduces melanoma cell metastasis.
  • Inhibition of NF-kappaB activation is a key mechanism for cAMP-mediated Tbeta4 downregulation.
  • Targeting cAMP pathways offers a promising strategy for anti-cancer therapies.

More Related Videos

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...